Effect of probucol in lecithin-cholesterol acyltransferase - Deficient mice: Inhibition of 2 independent cellular cholesterol - Releasing pathways in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 3, 2001, Pages 394-400

  Tomimoto, Shigehiro ^a   Tsujita, Maki ^a   Okazaki, Mitsuyo ^c   Usui, Shinichi ^c   Tada, Toyohiro ^b   Fukutomi, Tatsuya ^a   Ito, Shigenori ^a   Itoh, Makoto ^a   Yokoyama, Shinji ^a,b  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cholesterol efflux; Cholesterol homeostasis; High density lipoproteins; Lecithin cholesterol acyltransferase; Probucol

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOMEOSTASIS; HYPOLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN INTERACTION; REGULATORY MECHANISM;

EID: 0035093091     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.3.394     Document Type: Article

References (33)

1. Hydrolysis and excretion of cytoplasmic cholesterol esters by macrophages: Stimulation by high density lipoprotein and other agents
2. High density lipoprotein: The clinical implications of recent studies
3. Apolipoprotein-mediated cellular cholesterol efflux
4. Lecithin: Cholesterol acyltransferase deficiency and fish eye disease
5. Targeted disruption of the mouse lecithin: Cholesterol acyltransferase (LCAT) gene: Generation of a new animal model for human LCAT deficiency
6. Disruption of the murine lecithin: Cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type 1
7. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol
8. Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP
9. Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice
10. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease
11. Decreased reverse cholesterol transport from Tangier disease fibroblasts: Acceptor specificity and effect of brefeldin on lipid efflux
12. Mutations in ABC 1 in Tangier disease and familial high-density lipoprotein deficiency
13. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
14. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux
15. Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred
16. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
17. Tangier disease is caused by mutations in the gene encoding ATP binding-cassette transporter 1
18. Familial high density lipoprotein deficiency: Tangier disease
19. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
20. Analysis of lipoproteins by gel permeation chromatography
21. Regulation of lecithin-cholesterol acyltransferase reaction by acyl acceptors and demonstration of its "idling" reaction
22. The lecithin: Cholesterol acyltransferase reaction
23. Regulation of cellular cholesterol efflux by lecithin: Cholesterol acyltransferase reaction through nonspecific lipid exchange
24. Interaction of free apolipoproteins with macrophages: Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol
25. Involvement of cellular surface factor(s) in lipid-free apolipoprotein-mediated cellular cholesterol efflux
26. Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cholesterol efflux in macrophages
27. Antiatherogenic effects of the antioxidant BO-653 in three different animal models
28. Effects of probucol on xanthomata regression in familial hypercholesterolemia
29. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia
30. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I: Is the extent of atherosclerosis related to resistance of LDL to oxidation?
31. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
32. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors
33. 2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: A Probucol Quantitative Regression Swedish Trial (PQRST) Report